CBN got its reputation from old cannabis — the kind that had sat in a jar too long. It took until 2026 for anyone to put that reputation in front of a human sleep lab.
The short answer
Not for staying asleep. Possibly for falling asleep.
The first trial to measure CBN with overnight polysomnography — 20 adults with insomnia, single nights of 30 mg, 300 mg and placebo — missed its primary endpoint. Wake after sleep onset didn’t move (300 mg: −6.3 minutes, 95% CI −18.2 to +5.5, p = 0.29). At 300 mg people did fall asleep faster and record fewer brain-wave arousals. That is one night, twenty people, and a dose no gummy contains.
Key takeaways
- A 2021 review in Cannabis and Cannabinoid Research found insufficient published evidence for CBN’s sleep claims. Most human data dated to the 1970s–80s, and no clinical trial had used polysomnography.
- In rats, CBN raised non-REM sleep about as much as zolpidem — and also raised REM, which zolpidem doesn’t. That was 10–100 mg/kg by injection, not a gummy.
- A metabolite, 11-hydroxy-CBN, reached brain levels as high as CBN itself and hit CB1 receptors with potency comparable to THC. CBN alone was far weaker there.
- Sleep gummies commonly list 3–10 mg of CBN. The human trial’s 30 mg arm moved nothing it reported.
- The FDA has approved one cannabinoid medicine — a prescription seizure drug. Nothing on the sleep shelf is approved.
Where the story came from
CBN is cannabinol, present in hemp in tiny amounts next to CBD or THC. The plant barely makes it — it forms when THC sits in air, heat and light and slowly oxidises.
So the folklore is about degraded flower. Old, badly stored cannabis felt heavier, and the compound that had accumulated in it got the credit. That’s an origin story, not a mechanism.
On its own CBN is at most very mildly intoxicating; broad-spectrum and isolate products have the THC removed entirely.
What happened in the sleep lab
In 2026 the Journal of Sleep Research published the first randomised trial to measure CBN’s effect on sleep architecture directly.
Twenty adults with clinically confirmed insomnia (Insomnia Severity Index 15 or higher) took a single oral dose of 30 mg CBN, 300 mg CBN or placebo, two weeks apart, with overnight polysomnography each time. The target was wake after sleep onset — minutes awake once you’ve dropped off. It didn’t move.
| Measured overnight | 30 mg CBN | 300 mg CBN |
|---|---|---|
| Wake after sleep onset the primary endpoint | −4.0 min 95% CI −15.9 to +7.9 p = 0.50 | −6.3 min 95% CI −18.2 to +5.5 p = 0.29 |
| Time to fall asleep | No reported gain | Shorter — p = 0.004 |
| NREM-2 sleep | No reported gain | More — p = 0.03 |
| Brain-wave arousal index | No reported gain | Lower — p = 0.02 |
| Sleep quality, self-rated | No reported gain | Better — p = 0.005 |
How much weight that carries
- The endpoint the trial was built to answer came back null. Everything in the lower four rows is a secondary measure. Run enough of them and some will move.
- One night per dose, so nothing here speaks to a nightly habit.
- Twenty people — 17 women, 3 men, mean age 42. That size makes any single result fragile.
- 247 mild-to-moderate adverse events were logged across all three arms, placebo included.
The authors’ own conclusion: larger, longer trials are warranted.
The rat study everyone quotes
Before that, the headline finding was a University of Sydney study in Neuropsychopharmacology, which ran polysomnography on rats given 10, 30 or 100 mg/kg of CBN by injection against zolpidem at 10 mg/kg.
CBN increased total sleep time. Its effect on NREM matched zolpidem’s, and unlike zolpidem it also increased REM. The metabolite 11-hydroxy-CBN reached brain concentrations as high as CBN itself and was active at CB1 receptors with potency comparable to THC — CBN itself was much weaker there.
Two details rarely survive the retelling. The response was biphasic: sleep was suppressed first, then rose sharply. And these were rats, injected, at milligram-per-kilogram doses that don’t convert to a serving size.
The dose gap. Every measurable gain in the human trial came from the 300 mg arm. The 30 mg arm — already three to ten times what a typical sleep gummy lists — produced nothing the paper reported. The bottle in your hand and the bottle in the study are not the same experiment.
CBN, CBD and melatonin are not interchangeable
Melatonin is a timing signal — jet lag, shift work, a body clock running late. The American Academy of Sleep Medicine’s 2017 guideline suggests clinicians not use it for sleep onset or sleep maintenance insomnia in adults, on very low quality evidence.
CBD isn’t sedating. Whatever it does for sleep appears to run through easing the stress that keeps people awake, and the trial record is split rather than settled.
CBN is aimed at depth and wind-down. In the one human trial that measured it properly, the wind-down half partially held up and the staying-asleep half didn’t. Our CBD versus melatonin comparison covers which problem each fits.
Numbers from research and labels
There is no established CBN dose. Reference points, not a recommendation:
- Human trial: 30 mg and 300 mg, single oral doses.
- Animal work: 10–100 mg/kg injected, plus a 15-day repeated-dose arm at 10 mg/kg. Not translatable to a serving.
- Labels: commonly 3–10 mg CBN per serving, usually paired with 10–30 mg CBD.
- Timing: 30–60 minutes before bed for an oil; gummies go through digestion and can take up to two hours.
- Judging it: one product, one dose, a week or two — the method is in our beginner dosage guide.
Look for a per-serving milligram figure for CBN and CBD and a third-party certificate of analysis you can actually open. A combined “sleep blend” total tells you nothing.
Who should not try it
- Anyone on prescription medication. Cannabinoids compete for the liver enzymes that clear blood thinners, some antidepressants and seizure drugs. Ask your provider first.
- Pregnant or nursing. Don’t.
- Anyone subject to drug testing. CBN is a THC derivative. No hemp product can guarantee a clean screen.
- Anyone mixing it with alcohol or another sedative, or driving afterwards.
- Anyone whose insomnia has lasted weeks. That’s a provider, not a supplement — there may be a cause no gummy addresses.
So — is it worth buying?
As a low-stakes experiment, sure. As the fix for a night spent staring at the ceiling at 3am, the one proper trial says no — and retail doses sit an order of magnitude below the only arm that moved anything.
Do the free things first. A cool dark room, a schedule you hold on weekends and caffeine that stops early are where the real minutes are. If you keep snapping awake before dawn, start with why you wake up at 3am. Only then is a CBN gummy worth the money.
Questions people ask
Will CBN show up on a drug test?
It might. CBN is a THC derivative, and immunoassay screens are built to catch that family. “THC-free” describes what the extract had removed, not what a lab will read. If you’re tested at work, skip cannabinoids — no brand can promise a clean result.
Will CBN get me high?
Not the way THC does. It’s very mildly psychoactive at most, and broad-spectrum or isolate products have the THC stripped out. The human trial recorded only mild-to-moderate adverse events at both doses.
Is CBN legal?
Hemp-derived cannabinoids under 0.3% THC are federally legal in the US, but state law varies and several states restrict intoxicating hemp products specifically. Check your own state before ordering.
Can I take it with alcohol or a prescription sleep aid?
No. Stacking sedatives is how a mild compound becomes a problem, and cannabinoids share liver enzymes with a long list of prescriptions. If you’re already on a sleep medication, that conversation belongs with whoever prescribed it.
Does CBN leave you groggy the next morning?
It’s sold as the alternative to melatonin hangover, but the evidence is thin either way. The single-night trial logged 247 mild-to-moderate adverse events across all three arms — placebo included — so most weren’t specific to CBN. Nobody has published next-day data on nightly use.
Sources
- Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo-Controlled Crossover Trial — Journal of Sleep Research, 2026;35(4). doi:10.1111/jsr.70284.
- A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats — Neuropsychopharmacology, 2025;50:586–595.
- Cannabinol and Sleep: Separating Fact from Fiction — Cannabis and Cannabinoid Research, 2021;6(5):366–371.
- Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults — American Academy of Sleep Medicine, J Clin Sleep Med 2017;13:307–349.
- “Sleepy cannabis”: first objective study to show cannabinol increases sleep — University of Sydney, 2024.
- What You Need to Know About Products Containing Cannabis or Cannabis-Derived Compounds — U.S. Food and Drug Administration.
How we make money. Some links on this page are affiliate links. If you buy through one, we may earn a commission at no extra cost to you. It does not change what we write — see our affiliate disclosure.
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure or prevent any disease. Serene Leaf does not physically test products; our assessments are based on published research, third-party lab reports and publicly available product information.
This article is information, not medical advice. Talk to a qualified healthcare provider before starting any supplement — especially if you are pregnant, nursing, taking medication or managing a diagnosed condition. 21+ only.